Carmat SAS
This article was originally published in Start Up
Executive Summary
Paris-based start-up Carmat has developed an artificial replacement heart that relies on high-tech sensor technology similar to that used in satellites and airplanes. The result, according to the company, is an artificial heart capable of detecting the patient's needs and responding to them automatically. The Carmat heart is not a ventricular-assist device, but is designed as a permanent replacement for the diseased heart.
You may also be interested in...
Start-Up Previews (02/2009)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Building the Next-Generation of GPCR-Targeting Drugs," features profiles of Catena Pharmaceuticals, Dimerix Bioscience, Heptares Therapeutics and Trevena. Plus these Start-Ups Across Health Care: Carmat, Glycan Biosciences, Itero and MaRVis Technologies.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.